In 1998, Clay Siegall co-founded Seattle Genetics. He is the CEO, President, and Chairman of the Board. He is a scientist who focuses on targeted cancer therapies. Seattle Genetics was created through drug development, rigorous research, and scientific innovation. The company is developing antibody-drug conjugates, and Clay Siegall helped ensure ADCETRIS’ FDA approval. It is now a global brand sold in over 65 countries due to a Takeda Pharmaceutical Company collaboration.
Dr. Siegall has helped Seattle Genetics enter into various licenses for its ADC technology. The company’s technology has been used to develop over 20 ADCs. Siegall has secured over $1.2 billion using private and public financings. From 1991 to 1997, he worked at Bristol-Myers Squibb Pharmaceutical Research Institute. From 1988 to 1991, he worked at the National Cancer Institute, National Institutes of Health.
He sits on the Board of Directors of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and Washington Roundtable. In 2013, he has received the University of Maryland Alumnus of the Year for Math, Natural Sciences, and Computer. In 2012, he won the Pacific Northwest Ernst & Young Entrepreneur of the Year. He holds 15 patents and he has written over 70 publications. He attended George Washington University to earn his Ph.D. in Genetics. He earned his B.S. in Zoology at the University of Maryland. He watched his father’s cancer progress when he was a teenager. He discovered that there were limited oncology tools available at that time. He was determined to help patients and improve cancer treatments.
Clay Siegall recommends that entrepreneurs learn everything they can by interacting with people who are experts in different areas. A crucial component of his business strategy is collaborating with oncology drug development innovators and industry leaders. Seattle Genetic’s ADC collaborations have given the company the ability to place resources into new approaches and new ideas.